Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bevacizumab Biosimilar (ODDIFACT SAS), 贝伐珠单抗生物类似药(ODDIFACT SAS), BEVA24042 |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neurofibromatosis 2 | Preclinical | United States | 15 Jul 2024 | |
| Recurrent Respiratory Papillomatosis | Preclinical | United States | 02 Jul 2024 |






